Piramal Critical Care was built through strategic acquisitions and today we are the third largest player in the inhaled anaesthesia market. Moving forward, we are focused on expanding our global footprint through new product additions in the generic hospital injectable space and other niche areas.

Our Business Development team leads the evaluation of assets and the execution of agreements to support licensing, acquisitions, ANDA purchase, co-marketing and promotion, and similar strategic alliances. We currently seek opportunities that reflect our strategy of driving success by leveraging expertise and Piramal Critical Care will continue to rely on strategic partnerships to create a robust portfolio of products to better serve patients and providers.